Last updated: 2026-09-16 09:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
LB Pharmaceuticals Inc. (LBRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $45,41, with a market capitalisation of $1,45B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13,36 to $50,16. This page covers its latest market performance, valuation, price trends and company information.
$1,45B | |
$45,52 | |
$50,16 | |
$13,36 | |
$43,04 | |
-- | |
343,23K | |
-- | |
$50,16 | |
$13,36 | |
-- | |
-- |
LB Pharmaceuticals Inc. (LBRX) is trading at $45,41 in pre-market trading as of 2026-09-16 08:10:00, up 5,51% ($2,37) from the previous close of $43,04
Pre-market trading shows how investors are pricing LBRX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, LB Pharmaceuticals Inc. (LBRX) moved from $49,34 to $45,41, representing a decline of 7,96% ($3,93).
The stock traded between $42,50 and $49,91 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 234,80 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 87,1%
LBRX is currently trading at $45,41, placing it 87,1% of the way from its 52-week low of $13,36 to its 52-week high of $50,16. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 27 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of LB Pharmaceuticals Inc. (LBRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.